HK inno.N Corporation

195940KOSDAQPharmaceuticals

HK inno.N Corporation (195940, KOSDAQ) reported KRW 1,063bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202382966471,8481,204Separate
202489788621,8901,251Separate
20251,063111762,0971,328Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20238%5.7%65.1%3.9%
20249.8%6.9%66.2%4.9%
202510.4%7.1%63.3%5.7%

Revenue moved 28.3% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 1,133bn
Close priceKRW 40,000
Listed shares28,329,891
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)1,723
Women449 (26.1%)
Average tenure9 years
Annual pay, menKRW 88,915,228
Annual pay, womenKRW 72,278,396
Pay ratio, women to men81.3%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →